Toxicity and immunomodulatory activity of liposomal vectors formulated with cationic lipids toward immune effector cells
Open accessAbstract
Liposomal vectors formulated with cationic lipids (cationic liposomes) and fusogenic dioleoylphosphatidylethanolamine (DOPE) have potential for modulating the immune system by delivering gene or antisense oligonucleotide inside immune cells. The toxicity and the immunoadjuvant activity of cationic liposomes containing nucleic acids toward immune effector cells has not been investigated in detail. In this report, we have evaluated the toxicity of liposomes formulated with various cationic lipids towards murine macrophages and T lymphocytes and the human monocyte-like U937 cell line. The effect of these cationic liposomes on the synthesis of two immunomodulators produced by activated macrophages, nitric oxide (NO) and tumor necrosis factor-alpha (TNF-alpha), has also been determined. We have found that liposomes formulated from DOPE and cationic lipids based on diacyltrimethylammonium propane (dioleoyl-, dimyristoyl-, dipalmitoyl-, disteroyl-: DOTAP, DMTAP, DPTAP, DSTAP) or dimethyldioctadecylammonium bromide (DDAB) are highly toxic in vitro toward phagocytic cells (macrophages and U937 cells), but not towards non-phagocytic T lymphocytes. The rank order of toxicity was DOPE/DDAB > DOPE/DOTAP > DOPE/DMTAP > DOPE/DPTAP > DOPE/DSTAP. The ED50's for macrophage toxicity were < 10 nmol/ml for DOPE/DDAB, 12 nmol/ml for DOPE/DOTAP, 50 nmol/ml for DOPE/DMTAP, 400 nmol/ml for DOPE/DPTAP and > 1000 nmol/ml for DOPE/DSTAP. The incorporation of DNA (antisense oligonucleotide or plasmid vector) into the cationic liposomes marginally reduced their toxicity towards macrophages. Although toxicity was observed with cationic lipids alone, it was clearly enhanced by the presence of DOPE. The replacement of DOPE by dipalmitoylphosphatidylcholine (DPPC) significantly reduced liposome toxicity towards macrophages, and the presence of dipalmitoylphosphatidylethanolamine-PEG2000 (DPPE-PEG2000: 10 mol%) in the liposomes completely abolished this toxicity. Cationic liposomes, irrespective of their DNA content, downregulated NO and TNF-alpha synthesis by lipopolysaccharide (LPS)/interferon-gamma (IFN-gamma)-activated macrophages. The replacement of DOPE by DPPC, or the addition of DPPE-PEG2000, restored NO and TNF-alpha synthesis by activated macrophages. Since macrophages constitute the major site of liposome localization after parenteral administration and play an important role in the control of the immune system, cationic liposomes should be used with caution to deliver gene or antisense oligonucleotide to mammalian cells. Cationic lipids show in vitro toxicity toward phagocytic cells and inhibit in vitro and in situ NO and TNF-alpha production by activated macrophages.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The success of the first approved siRNA-LNP therapeutic and mRNA COVID-19 vaccines originates only from their delivery using ionizable lipid-containing LNPs.
“Based on the potential toxicity of liposomes in clinical application,25,26 the success of the first approved small interfering RNA-lipid nanoparticle (LNP) therapeutic27 and mRNA COVID-19 vaccines originates only from their delivery using ionizable lipid-containing LNPs,28, 29, 30”
From COVID-19 mRNA vaccines: Platforms and current developments (2022) · cites this paper as [26]
Cytotoxicity of lipid materials is a safety concern depending on the dose, lipid properties and cell types.
“Cytotoxicity of lipid materials is also a safety concern, depending on the dose, lipid properties and cell types176,177.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [177]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
The Pathophysiology of Tumor Necrosis Factors
VASSALLI, P. (1992) · Annual Review of Immunology · doi:10.1146/annurev.iy.10.040192.002211 · Cited by 1,874 · see citing works
The Cell Biology of Macrophage Activation
Adams, D. O., & Hamilton, T. A. (1984) · Annual Review of Immunology · doi:10.1146/annurev.iy.02.040184.001435 · Cited by 1,611 · see citing works
The role of dioleoyl phosphatidylethanolamine in cationic liposome mediated gene transfer
Farhood, H., Serbina, N. V., & Huang, L. (1995) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(95)80016-9 · Cited by 799 · see citing works
Systemic Gene Expression After Intravenous DNA Delivery into Adult Mice
Zhu, N. W., Liggitt, D., Liu, Y., & Debs, R. J. (1993) · Science · doi:10.1126/science.7687073 · Cited by 720 · see citing works
Liposome-mediated CFTR gene transfer to the nasal epithelium of patients with cystic fibrosis
Caplen, N. J., Alton, E. W. F. W., Mddleton, P. G., Dorin, J. R., Stevenson, B. J., Gao, X., Durham, S. R., Jeffery, P. K., Hodson, M. E., Coutelle, C. C., et al. (1995) · Nature Medicine · doi:10.1038/nm0195-39 · Cited by 710 · see citing works
Zhou, X., & Huang, L. (1994) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(94)90066-3 · Cited by 499 · see citing works
Phosphatodylethanolamine liposomes: drug delivery, gene transfer and immunodiagnostic applications
Litzinger, D. C., & Huang, L. (1992) · Biochimica et Biophysica Acta (BBA) - Reviews on Biomembranes · doi:10.1016/0304-4157(92)90039-d · Cited by 368 · see citing works
Chonn, A., Cullis, P. R., & Devine, D. V. (1991) · The Journal of Immunology · doi:10.4049/jimmunol.146.12.4234 · Cited by 367 · see citing works
Gene Transfer In Vivo with DNA–Liposome Complexes: Safety and Acute Toxicity in Mice
Stewart, M. J., Plautz, G. E., Buono, L. D., et al. (1992) · Human Gene Therapy · doi:10.1089/hum.1992.3.3-267 · Cited by 264 · see citing works
Effect of cationic cholesterol derivatives on gene transfer and protein kinase C activity
Farhood, H., Bottega, R., Epand, R. M., & Huang, L. (1992) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(92)90316-e · Cited by 240 · see citing works
Comparison of Cell Proliferation and Toxicity Assays Using Two Cationic Liposomes
Lappalainen, K., Jääskeläinen, I., Syrjänen, K. J., Urtti, A. O., & Syrjänen, S. (1994) · Pharmaceutical Research · doi:10.1023/a:1018932714745 · Cited by 238 · see citing works
Fate of cationic liposomes and their complex with oligonucleotive in vivo
Litzinger, D. C., Brown, J. M., Wala, I., Kaufman, S. A., han, G. Y., Farrell, C. L., & Collins, D. W. (1996) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(95)00268-5 · Cited by 201 · see citing works
Capaccioli, S., Dipasquale, G., Mini, E., Mazzei, T., & Quattrone, A. (1993) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1993.2552 · Cited by 170 · see citing works
Harding, C. V., Collins, D. S., Kanagawa, O., & Unanue, E. R. (1991) · The Journal of Immunology · doi:10.4049/jimmunol.147.9.2860 · Cited by 161 · see citing works
Interaction of positively-charged liposomes with blood: implications for their application in vivo
Senior, J. H., Trimble, K. R., & Maskiewicz, R. (1991) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(91)90160-a · Cited by 155 · see citing works
Kovacs, E. J., Radzioch, D., Young, H. A., et al. (1988) · The Journal of Immunology · doi:10.4049/jimmunol.141.9.3101 · Cited by 152 · see citing works
Aoki, K., Yoshida, T., Sügimura, T., & Terada, M. (1995) · PubMed · Cited by 151 · see citing works
Inhibition of protein kinase C by cationic amphiphiles
Bottega, R., & Epand, R. M. (1992) · Biochemistry · doi:10.1021/bi00152a045 · Cited by 143 · see citing works
Liposomes as agents of DNA transfer
Smith, J. G., Walzem, R. L., & German, J. B. (1993) · Biochimica et Biophysica Acta (BBA) - Reviews on Biomembranes · doi:10.1016/0304-4157(93)90004-8 · Cited by 135 · see citing works
Zhang, R., Yan, J., Shahinian, H., Amin, G., Lu, Z., Liu, T., Saag, M. S., Jiang, Z., Temsamani, J., Martin, R. R., et al. (1995) · Clinical Pharmacology & Therapeutics · doi:10.1016/0009-9236(95)90071-3 · Cited by 129 · see citing works
The role of protein kinase C in the induction of nitric oxide synthesis by murine macrophages
Severn, A., Wakelam, M. J. O., & Liew, F. Y. (1992) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(92)91330-s · Cited by 109 · see citing works
Canonico, A. E., Plitman, J. D., Conary, J. T., Meyrick, B. O., & Brigham, K. L. (1994) · Journal of Applied Physiology · doi:10.1152/jappl.1994.77.1.415 · Cited by 103 · see citing works
Vertut‐Doï, A., Ishiwata, H., & Miyajima, K. (1996) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(95)00185-9 · Cited by 88 · see citing works
Cytolytic activity of liposomes containing stearylamine
Yoshihara, E., & Nakae, T. (1986) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(86)90068-4 · Cited by 79 · see citing works
Velinova, M. J., Read, N. G., Kirby, C. J., et al. (1996) · Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism · doi:10.1016/0005-2760(95)00208-1 · Cited by 62 · see citing works
Nitric oxide, a vital poison inside the immune and inflammatory network
Dugas, B., Debré, P., & Moncada, S. (1995) · Research in Immunology · doi:10.1016/0923-2494(96)84914-5 · Cited by 57 · see citing works
Filion, M. C., Bradley, A. J., Devine, D. V., et al. (1995) · European Journal of Immunology · doi:10.1002/eji.1830251120 · Cited by 55 · see citing works
Self-citationAntisense oligonucleotide therapeutics: drug delivery and targeting
Rojanasakul, Y. (1996) · Advanced Drug Delivery Reviews · doi:10.1016/0169-409x(95)00020-8 · Cited by 55 · see citing works
[6] Use of liposomes as biodegradable and harmless adjuvants
van Rooijen, N., & van Nieuwmegen, R. (1983) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(83)93036-7 · Cited by 52 · see citing works
Filion, M., Proulx, C., Bradley, A., et al. (1996) · Blood · doi:10.1182/blood.v88.6.2144.bloodjournal8862144 · Cited by 50 · see citing works
Self-citationPhillips, N. C. (1996) · Vaccine · doi:10.1016/0264-410x(96)82949-5 · Cited by 49 · see citing works
Self-citationTan, L., & Gregoriadis, G. C. (1989) · Biochemical Society Transactions · doi:10.1042/bst0170690 · Cited by 18 · see citing works
Phillips, N. C., & Gagné, L. (1995) · Journal of drug targeting · doi:10.3109/10611869509059213 · Cited by 16 · see citing works
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Liposomal drug delivery systems: From concept to clinical applications
Allen, T. M., & Cullis, P. R. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.09.037 · Cited by 4,839 · see citing works
Lipid nanoparticles for mRNA delivery
Hou, X., Zaks, T., Langer, R., & Dong, Y. (2021) · Nature Reviews Materials · doi:10.1038/s41578-021-00358-0 · Cited by 4,076 · see citing works
Toxicity of cationic lipids and cationic polymers in gene delivery
Lv, H., Zhang, S., Wang, B., Cui, S., & Yan, J. (2006) · Journal of Controlled Release · doi:10.1016/j.jconrel.2006.04.014 · Cited by 2,286 · see citing works
Smart nanocarrier-based drug delivery systems for cancer therapy and toxicity studies: A review
Hossen, S., Hossain, M. K., Basher, M. K., Mia, M. N. H., Rahman, M. T., & Uddin, M. J. (2019) · Journal of Advanced Research · doi:10.1016/j.jare.2018.06.005 · Cited by 998 · see citing works
Ndeupen, S., Qin, Z., Jacobsen, S., Bouteau, A., Estanbouli, H., & Igyártó, B. Z. (2021) · iScience · doi:10.1016/j.isci.2021.103479 · Cited by 678 · see citing works
Opportunities and Challenges in the Delivery of mRNA-Based Vaccines
Wadhwa, A., Aljabbari, A., Lokras, A., Foged, C., & Thakur, A. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12020102 · Cited by 584 · see citing works
Multifunctional and stimuli-sensitive pharmaceutical nanocarriers
Torchilin, V. (2009) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2008.09.026 · Cited by 583 · see citing works
Lipid nanoparticles enabling gene therapies: from concepts to clinical utility
Kulkarni, J. A., Cullis, P. R., & van der Meel, R. (2018) · Nucleic Acid Therapeutics · doi:10.1089/nat.2018.0721 · Cited by 592 · see citing works
Tat peptide-mediated intracellular delivery of pharmaceutical nanocarriers
Torchilin, V. P. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.10.008 · Cited by 449 · see citing works
COVID-19 mRNA vaccines: Platforms and current developments
Szabó, G. T., Mahiny, A. J., & Vlatkovic, I. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.02.016 · Cited by 308 · see citing works
Cationic lipids activate intracellular signaling pathways
Lonez, C., Vandenbranden, M., & Ruysschaert, J.-M. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.05.009 · Cited by 221 · see citing works
Lipid nanoparticle-mediated drug delivery to the brain
Khare, P., Edgecomb, S. X., Hamadani, C. M., Tanner, E. E. L., & S Manickam, D. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114861 · Cited by 187 · see citing works
Mechanisms of nanoparticle-mediated siRNA transfection by melittin-derived peptides
Hou, K. K., Pan, H., Ratner, L., Schlesinger, P. H., & Wickline, S. A. (2013) · ACS Nano · doi:10.1021/nn403311c · Cited by 95 · see citing works
Tetranucleotide GGGA Motif in Primary RNA Transcripts
Tu, G.-C., Cao, Q.-N., Zhou, F., & Israel, Y. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.39.25125 · Cited by 93 · see citing works
Han, B., Zhang, R., Li, L., Hu, C., Li, M., Liu, J., Sun, X., Fan, W., Xie, J., & Lei, Y. (2023) · Journal of Materials Chemistry B · doi:10.1039/d3tb01430d · Cited by 11 · see citing works
- Authors
- Filion, M. C., & Phillips, N. C.
- Affiliations
- Université de Montréal (CA)
- Corresponding author
- Phillips, Nigel C
- Venue
- Biochimica et Biophysica Acta (BBA) - Biomembranes
- Publisher
- Elsevier BV
- Published
- 1997-10
- Volume
- 1329
- Issue
- 2
- Pages
- 345-356
- ISSN
- 0005-2736 (ISSN-L)
- OpenAlex
- W1984307295
- Cited by
- 428
- References
- 33
- Citations by year
- 2026: 6 · 2025: 22 · 2024: 21 · 2023: 23 · 2022: 18 · 2021: 28 · 2020: 21 · 2019: 13 · 2018: 18 · 2017: 12 · 2016: 17 · 2015: 10 · 2014: 17 · 2013: 22 · 2012: 21
- FWCI
- 2.73
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Biochimica et Biophysica Acta (BBA) - Biomembranes (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Keywords
- cationic liposomes, liposome toxicity, immunomodulation, macrophages, U937 cells, T cells, nitric oxide, TNF-α, DOTAP, didodecyldimethylammonium bromide, DOPE, DPPC, antisense oligonucleotides, plasmid DNA delivery, immunoadjuvant
- MeSH terms
- Quaternary Ammonium Compounds, Animals, Cell Line, Drug Carriers, Female, Genetic Vectors, Humans, Liposomes, Macrophage Activation, Monocytes, Phagocytosis, Phospholipids, Plasmids, Structure-Activity Relationship, T-Lymphocytes, Oligonucleotides, Antisense, Macrophages, Peritoneal, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
